In recent years, precision medicine has provided unprecedented possibilities for the transformation of the medical and pharmaceutical industry, from "one-size-fits-all" therapy to patient stratification in new drug research and development, and then to individualized prevention and treatment strategies.
With the rapid development of sequencing technology and the reduction of cost, more and more diseases can be diagnosed and treated early through molecular detection, which greatly promotes the expansion of the precision medical market. According to statistics, the global precision medical market is expected to exceed 150 billion US dollars by 2027.
In the hot track of precise medical molecular detection, Rendong Medical was not the first to be established, but after several years of efforts, it has become the leading brand of precise diagnosis and treatment of urinary tumors in China, as well as the leading enterprise of the integrated scheme of precise diagnosis and treatment of vertical diseases. How to succeed in overtaking in corners? Recently, the medical industry "Machinery" invited Ms. Golden Pigeon, founder and CEO of Rendong Medical Group, to talk about the precision medical industry.
Overtime under NGS,a big adventure for terminal cancer patients
"The best hospital and the best experts in Beijing have diagnosed me with stage III bladder cancer. The treatment plan is to cut off the whole bladder and bring a urine bag." In 2018, an investor friend said to Golden Pigeon on the phone.
The patient is a marathon enthusiast and is in the prime of life. He believes that the quality of life after this treatment is not satisfactory to him.
In the difficult choice between survival and quality of life, he asked almost all the world-renowned medical institutions and experts, but most of them, including some top experts in the United States, supported the total resection plan. Some experts suggest a more "radical" approach: building a "new bladder" with intestines, but continence will be affected, while others recommend bladder-preserving triple therapy (TMT), but there is a certain risk of recurrence.
At the suggestion of Golden Pigeon, the patient first used the tissue of TURBT (transurethral resection of bladder tumor) to do the large Panel test of bladder cancer customized by Rendong, and the result was that the tumor mutation load (TMB) was high (19.1/Mb) and accompanied by RB1 gene inactivation mutation, suggesting that it might benefit from immunotherapy (PD-1/L1 drugs).
However, at that time, PD-1/L1 drugs were only approved for second-line treatment of advanced urothelial cancer worldwide, without indications for TMT therapy or even the results of early clinical trials, so some experts were skeptical: PD-1/L1 drugs are equivalent to "nuclear weapons", and you can't put the best weapons in front of them.
Finally, the patient adopted the suggestion of expert consultation and discussion organized by Rendong Medical Organization: the TMT treatment plan combined with PD-1/L1 drugs should be used at the first time. The result is also gratifying, his condition has reached a sustained complete remission (CR), and he is still active on the investment track today. Rendong Medical regularly monitors his urine dynamically in order to adjust the treatment plan and dosage. This urine product is also the prototype of the methylation detection product for urothelial cancer.
Golden Pigeon joked, "He is our'white mouse '." Around this experience, the attending doctor wrote a case report, published in the Journal of Frontiers in Immunology, with an impact factor of 7-8.

Fig.1 Case report, pictures provided by the enterprises interviewed
Now it seems that the patient has received better neoadjuvant therapy (a pretreatment with drugs or other means before surgery or other treatment methods, aiming at improving the condition and improving the therapeutic effect). At that time, this practice was very bold and risky-there was no evidence-based basis for over-indication medication. But in the end, relying on excellent genetic testing technology and expert's careful treatment, he won the "overtime game". Later, pharmaceutical companies such as Rendong Medical and Baekje carried out multi-center clinical studies on the treatment of urothelial cancer patients based on the PD-L1 neoadjuvant regimen. It is reported that the articles related to the study have been submitted to Nature Cancer by Professor Huang Jian of Sun Yat-sen Hospital of Sun Yat-sen University as the corresponding author.
Build the integration of diagnosis and treatment in the field of urology
"We really helped the people around us, and the clinicians were very happy, not only effective, but also able to send out articles! This positive feedback shows that we are worth doing, and we should continue to do it."
Golden Pigeon laments that when she started her business in her early 30s, almost no one around her had cancer, but as she grew older and experienced it personally, she felt more deeply about the value orientation of Rendong Medicine, that is, "helping clinical translational research and assisting key clinical decision-making".
She said that a 26-year-old man with suspected VHL syndrome [OMIM 193300 caused by mutation of VHL tumor suppressor gene, VHL patients with multi-organ tumor syndrome] was scratching his head in search of consultation from multiple head hospitals to confirm the diagnosis. Finally found "hope" in the patient group-learned that Rendong medicine is famous for its urology specialty in the industry, contacted Rendong for the first time to do relevant tests and diagnose the disease, and sighed with emotion: the technology industry has specialized, professional institutions do professional things.
Considering that the man already had children, Rendong Medical also provided family testing for him and found that both the man and the child were carriers of the VHL mutation gene. Although no new drug for VHL syndrome has been approved yet, Rendong Medical has recommended it to the clinical trials of its cooperative pharmaceutical companies, because the new drug (HIF2α inhibitor) it is promoting can just treat the disease. This is also in line with the concept of Rendong Medical Whole Process Management, not only to give a test report, but also to give follow-up supporting solutions.
"This is a VHL diagnostic reagent developed by us and the Institute of Urology of Peking University. It is not cost-effective in terms of input-output ratio, but it is very valuable in clinical practice." Golden Pigeon said that this is a rare tumor that often grows in the adrenal gland, with an incidence of about 1/36000, and the population is concentrated. Generally, patients need to go to the Department of Urology and Renal Oncology for diagnosis and treatment, and there are only 3-4 top experts in the country.
Today, Rendong Medical has grown into a leading enterprise in the field of urological oncology subdivision in China, and its products have formed perfect solutions in the field of urological oncology (prostate cancer, bladder cancer, kidney cancer), leading in market recognition and share.
On this basis, Rendong Medical also actively assists pharmaceutical companies in evidence-based medicine before and after listing through a unique large data accumulation model, introduces international advanced technology to develop products based on Chinese characteristics, and does a good job in patient management for a long time.

Fig.2 Based on the largest urology database in China, Rendong Medical improves the layout of IVD around the advantages of multi-omics.
From Top-Tier Hospitals to Grassroots Communities: How Gene Sequencing is Prying Open More Urology Market Share
In addition to the basic plate of sequencing products in the field of urological oncology, Rendong Medical has been actively developing and introducing innovative products for consumers in recent years, covering the whole urological specialty from oncology, such as
Urine-a methylation product based on early screening and adjunctive diagnosis of urothelial cancer.
Uniqal/Uniqal-Urinary Tract Pathogenic Microorganism/Drug Resistance Gene Products for Urinary Tract Infection.
PSEP-a prostatic corpuscle protein detection product for the diagnosis of prostatitis.

Fig.3 Innovative New Products of Rendong Medical Urology Department
Golden pigeon introduced that patients with urothelial cancer should use cystoscopy in the initial and follow-up stages. The cost of cystoscopy is relatively high (ordinary laboratory tests), which belongs to invasive examination. For men, the operation process is very painful, and the probability of hematuria after examination is 2-3 days.
Rendong Medical has developed a full cycle of technology from early detection to dynamic monitoring around the precise diagnosis of urothelial cancer. On the basis of TCGA database and gene chip analysis, large-scale clinical sample verification has been carried out to discover the unique methylation sites of urothelial cancer genes in Chinese population, thus building a knowledge system to protect them.
Golden Pigeon is very proud of this C-end, relatively lightweight product-excellent secretion: "China's molecular diagnostic market is very large, and we feel it is very valuable to make products that people in the county and village can afford and use."
Small colored egg:
The Inner Monologue of the Post-80s Female Entrepreneurs:Day arch a pawn, merit not Tang donation
Q: In the context of economic contraction and consumption downgrade, do you worry that your market is not big enough?
A: Business management is nothing more than revenue, profit, organizational talent and strategic implementation, so I hope that my business is solid, and I can do it every day. In fact, there is no small market, especially in today's China and globalization. Unique value refers not only to good products, but also to deep ploughing and fine track. This is our ninth year, and we are going to do it slowly for twenty or thirty years. Good products, good channels and good brands require barriers day after day.
Q: Does Rendong Medical have a small revenue target?
A: In fact, most of our generation of entrepreneurs do not regard making money as their goal, but the ability to make money is the basic skill of entrepreneurs, which is a technical work of professional division of labor. We grew up in the context of reform and opening up and rapid economic development, so we feel that we love this thing, and then work with our favorite partners to improve technology, products and business, so that customers and patients can benefit.
Q: Why does describe himself as a "pessimistic optimist"?
A: Pessimism is preceded by an attribute. In this state of the capital market, everyone will be very cautious. However, in the long run, I am still very optimistic. I participated in international competition, took the money of the smartest capital, had a strong comprehensive ability of my team, and happened to work with a group of post-75 and post-80 excellent clinical experts to do basic innovation and clinical product transformation. I think this may be a unique opportunity in the past ten years and difficult to repeat in the next ten years. We should cherish it. In the past, big water and big fish gave us relatively abundant resources to do innovative practice, but now the tight days are just doing fine management practice on the basis of past consumption.
Q: What do you think is the biggest change in China's innovation market in recent years?
A: In the past, a drug/device could be sold for 20 years. A foreign-funded enterprise made an original research product, and we made a Me-too product. The former did market education, and when it matured, we covered it more widely at a lower price. In the innovation market of the past ten years, we have to go to the education market with foreigners. For the vast majority of Chinese people, we have not yet formed a systematic methodology for this matter, and the cost is very high. But the good news is that clinicians now do not think that domestic brands are necessarily inferior to imports, which I think is a great progress in the past few years.
Q: After so many years in business, what do you think about when you're at your lowest?
A: We have taken a lot of money from investors for so many years. At the darkest time, we will feel that your only value may be to pay hundreds of employees of the company, at least to support so many families. This is also the social value of an entrepreneur.
Q: Now everyone is concerned about going to sea. Does Rendong Medical have this consideration?
A: We are all paying close attention to the opportunity of going to sea. Only when product-based companies allocate R & D to the broad market can they really have the power of continuous R & D.